PTC Therapeutics prices $500M convertible notes at 0% to refinance 2026 debt
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
June 15, 2026 11:14 PM EDTRefinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity
Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026
WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing... More
